CatalystAlertBeta

Briefing Calendar News IPOs Catalyst Radar Research Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

CatalystAlert is a biotech catalyst intelligence platform tracking FDA decisions, PDUFA dates, and clinical-trial readouts for 1,600+ biotech stocks. Every catalyst date carries a confidence rating — confirmed against an official regulatory source, estimated, or AI-detected — alongside AI entry-timing and a public, scored prediction track record.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary
Best Catalyst Tools
What's New

Compare

vs BioPharmCatalyst
vs BioMarkets.io
vs Biocat
vs BioCatalyst
vs ClinicalInvestor

Legal

About
CeliA (AI assistant)
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

Legal & disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All signals, probability scores, and analyses are based on historical data and machine-learning models. Past performance does not guarantee future results, and biotech is a volatile sector where outcomes are uncertain.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar Watchlist News Learn Account

Nipocalimab - Phase 3 | JNJ Pipeline | CatalystAlert

Nipocalimab

Phase 3

Johnson & Johnson (JNJ)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

JNJPhase 3$549.8B

Nipocalimab Phase 3 Est. Readout

Nipocalimab• Arthritis, Rheumatoid201

Q2 2027~QConfirmed

00%

Competitive Landscape

1 competitor in Arthritis, Rheumatoid

View Full Landscape

Drug Information

Target Indication

Arthritis, Rheumatoid

Clinical Trial

Last updated: 5/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/28/2025

Imaavy

Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

risperidone oral tabletsPhase 3

Anxiety Disorders

DoxorubicinPhase 3

Sarcoma

CG 5503;tapentadolPhase 3

Osteoarthritis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.